666-To The Moon - Tiger Brokers Online Investing Community - To The Moon

2
Comment
Favorite

lwj1
2021-08-19

666

心玮医疗-B(06609.HK)香港公开发售获333.14倍认购上限定价每股171港元

根据香港公开发售初步提呈发售的香港发售股份获非常大幅超额认购。合共接获235,040份有效申请，认购合共2.199亿股香港发售股份，相当于根据香港公开发售初步可供认购的H股总数约333.14倍。根据发售价每股H股171.00港元，公司自全球发售收取的所得款项净额估计约为10.148亿港元。

心玮医疗-B(06609.HK)香港公开发售获333.14倍认购上限定价每股171港元

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

2

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":831211017,"tweetId":"831211017","gmtCreate":1629329676939,"gmtModify":1676530002473,"author":{"id":3585303194220633,"idStr":"3585303194220633","authorId":3585303194220633,"authorIdStr":"3585303194220633","name":"lwj1","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>666</p></body></html>","htmlText":"<html><head></head><body><p>666</p></body></html>","text":"666","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/831211017","repostId":2160753051,"repostType":2,"repost":{"id":"2160753051","kind":"news","pubTimestamp":1629325545,"share":"https://www.laohu8.com/m/news/2160753051?lang=&edition=full","pubTime":"2021-08-19 06:25","market":"hk","language":"zh","title":"心玮医疗-B(06609.HK)香港公开发售获333.14倍认购 上限定价每股171港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2160753051","media":"格隆汇","summary":"根据香港公开发售初步提呈发售的香港发售股份获非常大幅超额认购。合共接获235,040份有效申请，认购合共2.199亿股香港发售股份，相当于根据香港公开发售初步可供认购的H股总数约333.14倍。根据发售价每股H股171.00港元，公司自全球发售收取的所得款项净额估计约为10.148亿港元。","content":"<html><body><p>格隆汇8月19日丨<span><a href=\"https://laohu8.com/S/06609\">心玮医疗-B</a>(06609.HK)发布公告，公司全球发售660.185万股股份，其中香港发售股份330.1万股，国际发售股份330.085万股，另有15%超额配股权；发售价已厘定为每股发售股份171.00港元，每手买卖单位50股；<a href=\"https://laohu8.com/S/GS\">高盛</a>及<a href=\"https://laohu8.com/S/601995\">中金公司</a>为联席保荐人，预期股份将于2021年8月20日于联交所主板挂牌上市。</span></p><p>根据国际发售初步提呈发售的H股已获超额认购，相当于根据国际发售初步可供认购的H股总数约8.3倍。根据香港公开发售初步提呈发售的香港发售股份获非常大幅超额认购。合共接获235,040份有效申请，认购合共2.199亿股香港发售股份，相当于根据香港公开发售初步可供认购的H股总数约333.14倍。</p><p>基于每股发售价为171.00港元，根据相关基石投资协议，基石投资者已认购合共300.06万股H股，合共相当于紧随全球发售完成后公司已发行股本约7.73%及全球发售的发售股份数目约45.45%，在两种情况下均假设超额配股权并无获行使。</p><p>根据发售价每股H股171.00港元，公司自全球发售收取的所得款项净额估计约为10.148亿港元(假设超额配股权并无获行使)。公司拟将所得款项净额约45.3%分配至公司的核心产品；约39.9%所得款项净额预期将分配至公司管线内的其他在研产品；约4.8%所得款项净额用于为透过内部研究提升研发能力及持续扩充产品组合提供资金；约10.0%所得款项净额预期将用作营运资金及一般企业用途。</p></body></html>","source":"stock_gelonghui","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>心玮医疗-B(06609.HK)香港公开发售获333.14倍认购 上限定价每股171港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n心玮医疗-B(06609.HK)香港公开发售获333.14倍认购 上限定价每股171港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-19 06:25 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/news/detail.html?id=602138><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇8月19日丨心玮医疗-B(06609.HK)发布公告，公司全球发售660.185万股股份，其中香港发售股份330.1万股，国际发售股份330.085万股，另有15%超额配股权；发售价已厘定为每股发售股份171.00港元，每手买卖单位50股；高盛及中金公司为联席保荐人，预期股份将于2021年8月20日于联交所主板挂牌上市。根据国际发售初步提呈发售的H股已获超额认购，相当于根据国际发售初步可供...</p>\n\n<a href=\"https://www.gelonghui.com/news/detail.html?id=602138\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/cb94707725a5c97e34b5305626765aec","relate_stocks":{"06609":"心玮医疗-B"},"source_url":"https://www.gelonghui.com/news/detail.html?id=602138","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160753051","content_text":"格隆汇8月19日丨心玮医疗-B(06609.HK)发布公告，公司全球发售660.185万股股份，其中香港发售股份330.1万股，国际发售股份330.085万股，另有15%超额配股权；发售价已厘定为每股发售股份171.00港元，每手买卖单位50股；高盛及中金公司为联席保荐人，预期股份将于2021年8月20日于联交所主板挂牌上市。根据国际发售初步提呈发售的H股已获超额认购，相当于根据国际发售初步可供认购的H股总数约8.3倍。根据香港公开发售初步提呈发售的香港发售股份获非常大幅超额认购。合共接获235,040份有效申请，认购合共2.199亿股香港发售股份，相当于根据香港公开发售初步可供认购的H股总数约333.14倍。基于每股发售价为171.00港元，根据相关基石投资协议，基石投资者已认购合共300.06万股H股，合共相当于紧随全球发售完成后公司已发行股本约7.73%及全球发售的发售股份数目约45.45%，在两种情况下均假设超额配股权并无获行使。根据发售价每股H股171.00港元，公司自全球发售收取的所得款项净额估计约为10.148亿港元(假设超额配股权并无获行使)。公司拟将所得款项净额约45.3%分配至公司的核心产品；约39.9%所得款项净额预期将分配至公司管线内的其他在研产品；约4.8%所得款项净额用于为透过内部研究提升研发能力及持续扩充产品组合提供资金；约10.0%所得款项净额预期将用作营运资金及一般企业用途。","news_type":1},"isVote":1,"tweetType":1,"viewCount":596,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}